GILT REQUIRED FOR RTL550-CYS-MOG TO TREAT EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS

Míreanna Comhchosúla

• Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis
  le: Sinha, Sushmita, et al.
  Foilsithe: (2010)
• HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection
  le: Benedek, Gil, et al.
  Foilsithe: (2015)
• IL-13-Mediated Gender Difference in Susceptibility to Autoimmune Encephalomyelitis
  le: Sinha, Sushmita, et al.
  Foilsithe: (2008)
• Cytokine Switch and Bystander Suppression of Autoimmune Responses to Multiple Antigens in Experimental Autoimmune Encephalomyelitis by a Single Recombinant T-Cell Receptor Ligand
  le: Sinha, Sushmita, et al.
  Foilsithe: (2009)
• A Promising Therapeutic Approach for Multiple Sclerosis: Recombinant T-Cell Receptor Ligands Modulate Experimental Autoimmune Encephalomyelitis by Reducing Interleukin-17 Production and Inhibiting Migration of Encephalitogenic Cells into the CNS
  le: Sinha, Sushmita, et al.
  Foilsithe: (2007)